CN1736417A - Composition for treating upper respiratory tract infection and application - Google Patents
Composition for treating upper respiratory tract infection and application Download PDFInfo
- Publication number
- CN1736417A CN1736417A CN 200510041148 CN200510041148A CN1736417A CN 1736417 A CN1736417 A CN 1736417A CN 200510041148 CN200510041148 CN 200510041148 CN 200510041148 A CN200510041148 A CN 200510041148A CN 1736417 A CN1736417 A CN 1736417A
- Authority
- CN
- China
- Prior art keywords
- litsea cubeba
- cubeba oil
- oleum eucalypti
- compositions
- oleum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a composition comprising litsea cubeba oil and eucalyptus oil by the weight ratio of 1:0.1-10. The composition has the actions of dispersing pathogenic wind, relieving pain, relieving cough and resolving phlegm.
Description
Technical field
The present invention relates to a kind of compositions that comprises litsea cubeba oil and Oleum Eucalypti, said composition is preferred for treating upper respiratory tract infection, as acute/chronic bronchitis, acute and chronic nasal sinusitis and acute and chronic rhinitis etc.
Background technology
Upper respiratory tract infection is one of modal disease, the main respiratory mucosa inflammation that causes by bacterial infection, physics, chemical stimulation or allergin, cold, moist environment usually is this Disease Inducement, and the infection of virus also usually is the key factor of this type of disease incidence.The disease initial stage, the respiratory mucosa congestion and edema, polymorphonuclear granulocyte and lymphocyte infiltration mucosa make the respiratory tract endocrine increase.After granulocyte entered mucus, mucus will become purulence.Along with the development of the course of disease, dry cough can appear in patient, and produces sticking expectorant.This sticking expectorant can bring great misery to the patient because of the very big and difficult discharge of its viscosity.
Because the risk factor of upper respiratory tract infection is a lot, is difficult to find out its cause of disease clinically and etiological treatment.In this case, the doctor can use antibiotic to the patient mostly.Though this clinically disease often is mixed with bacterial infection, the life-time service antibiotic is uneconomic behavior, and can cause the increase of bacterial drug resistance.Under normal conditions, give the improvement that patient's expectorant helps patient's symptom, alleviate patient's misery.
Because nasal cavity, nasal sinuses are the outermost doors of respiratory tract, are subjected to the invasion and attack of various paathogenic factors easily.Therefore, rhinitis, sinusitis are the most common.According to statistics, in all upper respiratory tract infection patients, the rhinitis that the degree that occurs together more than 90% is different, sinusitis symptom.The foreign statistic data shows that on average acute rhinitis, sinusitis frequency are 2-3 time for each person every year, in the heavier urban area of air pollution, this is digital taller go out many.Nearly all with nasal obstruction, watery nasal discharge, hypopnea, severe patient also can have dizziness headache for acute rhinitis, sinusitis, and hypomnesis has a strong impact on patients ' life quality and ability to work, and long-term outbreak also can cause hyposmia, brings out nasal polyp.The present situation that " curing the symptoms, not the disease abuse of antibiotics " is the treatment acute and chronic rhinitis, sinusitis is very general.
Fructus Litseae is a Lauraceae Litsea plant, bright again cubeb litsen tree, Fructus Litseae.Litsea cubeba oil has antifungal, antibacterium, antiallergic, relieving asthma and multiple effect such as arrhythmia.Oleum Eucalypti is the common spice of China, and the effect of expelling phlegm for arresting cough is arranged, and Oleum Eucalypti sugar, Oleum Eucalypti buccal tablet are known by people for a long time.Main component in the Oleum Eucalypti is an eucalyptol, has the effect of wind-expelling pain-stopping, relieving cough and resolving phlegm.
Summary of the invention
The purpose of this invention is to provide a kind of compositions that includes litsea cubeba oil and Oleum Eucalypti.
Another object of the present invention provides the application of compositions in the medicine of preparation treatment upper respiratory tract infection of litsea cubeba oil and Oleum Eucalypti.
Purpose of the present invention can reach by following measure:
Compositions provided by the present invention is characterized in that being made up of litsea cubeba oil and Oleum Eucalypti, and the weight ratio of litsea cubeba oil and Oleum Eucalypti is 1: 0.1～10.
Purpose of the present invention can also reach by following measure:
Compositions provided by the invention is characterized in that the weight ratio preferred 1: 0.2～2 of litsea cubeba oil and Oleum Eucalypti.
Compositions provided by the invention is characterized in that also can containing medicinal diluent and medical additive except containing litsea cubeba oil and Oleum Eucalypti.
Compositions provided by the invention, the weight ratio that it is characterized in that litsea cubeba oil/Oleum Eucalypti and diluent is 1: 0.2～5, preferred 1: 0.5～2.
Compositions provided by the present invention is in preparation treatment upper respiratory tract infection, as the application in the medicine of acute/chronic bronchitis, acute and chronic nasal sinusitis and acute and chronic rhinitis.
The present invention will be described further further combined with specific embodiment, and these examples only are used for illustration purpose, and are not used in the restriction scope of the invention.
The specific embodiment
Embodiment 1: litsea cubeba oil/Oleum Eucalypti is to the phlegm-dispelling functions (the phenol red method of trachea section) of mice
Mice is divided into four groups at random by body weight, blank group (normal saline is only irritated stomach 0.5ml/), gastric infusion group (0.1g/kg, 0.2g/kg, 0.3g/kg).After 1 hour, lumbar injection 0.5% phenol red solution 0.5ml/ only puts to death animal after 30 minutes, peel off the trachea surrounding tissue, under thyroid cartilage, cut a kerf, draw 0.5ml alkalescence normal saline flushing trachea with the irrigation stomach device syringe needle, draw tracheal secretion, continuous four times, merge the tracheorrhaphy bleeding, with 721 type spectrophotometers, wavelength 546 is surveyed the OD value, with phenol red work one standard curve, according to the phenol red content of curve calculation (μ g/ml), and with matched group relatively.The result shows that litsea cubeba oil/Oleum Eucalypti can increase the phenol red eliminating amount of airway of mice (seeing Table 1), thereby illustrates that it can increase bronchial secretory volume dilution sputum, can promote expectoration.
Table 1 litsea cubeba oil/Oleum Eucalypti is to the phlegm-dispelling functions (the phenol red method of trachea section) of mice
| Group | Dosage (g/kg) | Irrigating solution phenol red concentration (x ± s, μ g/ml) |
| Matched group | The equal-volume solvent | 2.382±0.534 |
| Litsea cubeba oil/Oleum Eucalypti (1: 1) | 0.1 | 3.232±1.065 * |
| 0.2 | 3.591±1.114 ** | |
| 0.3 | 4.009±1.316 ** | |
| Litsea cubeba oil/Oleum Eucalypti (2: 1) | 0.1 | 3.531±1.322 * |
| 0.2 | 3.624±1.103 ** | |
| 0.3 | 3.879±1.256 ** | |
| Litsea cubeba oil/Oleum Eucalypti (1: 2) | 0.1 | 3.356±1.123 * |
| 0.2 | 3.985±1.156 ** | |
| 0.3 | 4.1139±1.055 ** |
Annotate: compare with the blank group:
*P＜0.05,
*P＜0.01
Embodiment 2: litsea cubeba oil/Oleum Eucalypti (1: 1) is to the antiinflammatory action (mice ear method) of mice
Get healthy male mice and be divided into four groups at random, blank group (normal saline is only irritated stomach 0.5ml/), gastric infusion group (0.2g/kg, 0.4g/kg, 0.6g/kg), after administration half an hour, every mice left side ear is smeared Oleum Tiglii mixing proinflammatory agent 25, put to death animal after 4 hours, laying identical big or small auricle with 9mm steel blunderbuss in the same position of ear weighs, with left and right sides Mus dropsy of ear weightening finish expression edema degree, the result shows (seeing Table 2), Oleum Tiglii is caused the mice ear that inflammation causes the obvious suppression effect, and is good dose-effect relationship.
Table 2 litsea cubeba oil/Oleum Eucalypti is to the antiinflammatory action of mice
| Group | Dosage (g/kg) | Two ear weight differences (x ± s, μ g/ml) |
| Blank | The equal-volume solvent | 33.00±3.19 |
| 1 | 0.2 | 29.55±3.26 * |
| 2 | 0.4 | 26.36±2.81 ** |
| 3 | 0.6 | 22.36±2.19 *** |
Annotate: compare with the blank group:
*P＜0.05,
*P＜0.01,
* *P＜0.001
Embodiment 3: prescription is formed
Pharmaceutical composition provided by the invention contains litsea cubeba oil, Oleum Eucalypti, medicinal diluent and pharmaceutic adjuvant.This Pharmaceutical composition can be by oral, local and vein mode administration, preferred oral administration.
With the soft capsule is example: with gelatin, glycerol, water are the capsule material, and Ni Baijin second fat is antiseptic.Therefore litsea cubeba oil/Oleum Eucalypti has transudation to the capsule material, adds diluent (refined plant oil), and the ratio of litsea cubeba oil/Oleum Eucalypti and diluent can be 1: 0.2～and 5, preferred 1: 0.5～2.Each capsule contains litsea cubeba oil/Oleum Eucalypti (1: 0.1～10) 50mg～350mg.
Claims (6)
1. the compositions of litsea cubeba oil and Oleum Eucalypti is characterized in that being made up of litsea cubeba oil and Oleum Eucalypti, and the weight ratio of litsea cubeba oil and Oleum Eucalypti is 1: 0.1～10.
2. the compositions of litsea cubeba oil according to claim 1 and Oleum Eucalypti, the weight ratio that it is characterized in that litsea cubeba oil and Oleum Eucalypti is 1: 0.2～2.
3. the compositions of litsea cubeba oil according to claim 1 and Oleum Eucalypti is characterized in that also can containing medicinal diluent and medical additive except containing litsea cubeba oil and Oleum Eucalypti.
4. the compositions of litsea cubeba oil according to claim 3 and Oleum Eucalypti, the weight ratio of litsea cubeba oil/Oleum Eucalypti and diluent are 1: 0.2～5.
5. the compositions of litsea cubeba oil according to claim 4 and Oleum Eucalypti, the weight ratio of litsea cubeba oil/Oleum Eucalypti and diluent are 1: 0.5～2.
6. the application of the compositions of the litsea cubeba oil of any one qualification and Oleum Eucalypti in the medicine of preparation treatment acute/chronic bronchitis, acute and chronic nasal sinusitis and acute and chronic rhinitis in the claim 1～5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041148 CN1736417A (en) | 2005-07-22 | 2005-07-22 | Composition for treating upper respiratory tract infection and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041148 CN1736417A (en) | 2005-07-22 | 2005-07-22 | Composition for treating upper respiratory tract infection and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1736417A true CN1736417A (en) | 2006-02-22 |
Family
ID=36079489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510041148 Pending CN1736417A (en) | 2005-07-22 | 2005-07-22 | Composition for treating upper respiratory tract infection and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1736417A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655709A (en) * | 2013-12-25 | 2014-03-26 | 成都乾坤动物药业有限公司 | Scutellaria baicalensis-containing veterinary medicine composition capable of treating respiratory disease syndromes of livestock |
| CN103655708A (en) * | 2013-12-25 | 2014-03-26 | 成都乾坤动物药业有限公司 | Honeysuckle-containing veterinary medicine composition capable of treating respiratory disease syndromes of livestock |
-
2005
- 2005-07-22 CN CN 200510041148 patent/CN1736417A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655709A (en) * | 2013-12-25 | 2014-03-26 | 成都乾坤动物药业有限公司 | Scutellaria baicalensis-containing veterinary medicine composition capable of treating respiratory disease syndromes of livestock |
| CN103655708A (en) * | 2013-12-25 | 2014-03-26 | 成都乾坤动物药业有限公司 | Honeysuckle-containing veterinary medicine composition capable of treating respiratory disease syndromes of livestock |
| CN103655708B (en) * | 2013-12-25 | 2016-05-25 | 成都乾坤动物药业有限公司 | The syndromic veterinary drug composition of a kind for the treatment of livestock and birds respiratory disease that contains honeysuckle |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Agarwal et al. | An evaluation of the efficacy of licorice gargle for attenuating postoperative sore throat: a prospective, randomized, single-blind study | |
| CN101549060B (en) | Medicament containing gnetales for treating bronchitis and preparation method thereof | |
| CN1899406A (en) | Chinese medicinal powder for treating rhinitis and its preparing method | |
| CN104116914A (en) | Composition for treating anaphylactic rhinitis and drug pillow made of same | |
| CN1736417A (en) | Composition for treating upper respiratory tract infection and application | |
| CN114767824B (en) | Preparation for treating laryngeal cough and preparation method thereof | |
| CN1294930C (en) | Medication for treating cough caused by inflammation of upper respiratory tract | |
| CN1284585C (en) | Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method | |
| CN101049485A (en) | Mulberry - ginger soft capsule for treating common cold, and preparation method | |
| CN1294931C (en) | Compound collunarium oil and preparation method thereof | |
| CN1559462A (en) | Compound nasal drop-oil, and its prepn. method | |
| Dusitkasem et al. | Ketamine Lubrication of Endotracheal Tubes for Attenuating Postoperative Sore Throat: a Randomized, Double-Blind Study | |
| Ommi et al. | Complementary effects of Mentha piperita (Peppermint) and Rosa damascene extract (Rose oil) on SpO2 in patients with COVID-19: a Randomized Clinical Trial | |
| CN109692255A (en) | A kind of Chinese medicine composition and its preparation method and application for treating acute tracheobronchitis | |
| CN110721303A (en) | Traditional Chinese medicine composition for treating allergic rhinitis and application thereof | |
| CN1294976C (en) | Oral medicine for treating gastro intestinal diseases and preparing method thereof | |
| CN109568428B (en) | Yongquan plaster for children | |
| JP2006008540A (en) | Cold remedy | |
| CN116531457B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and application thereof | |
| CN115252724B (en) | Traditional Chinese medicine composition for treating pharyngitis, product and preparation method | |
| خالد حسين فايد | Effects of Dexamethasone, Lidocaine, Dexamethasone and Lidocaine Together on Patient Undergoing Laparoscopic Cholecystectomy to Prevent Sore Throat, Cough and Hoarseness | |
| CN113633717B (en) | Electronic atomized liquid composition for nasal cavity care, application thereof and obtained care product | |
| CN1062446C (en) | Anti-allergy disease preparation | |
| Thangaraju et al. | Effectiveness of turmeric-based lozenges in reducing the postoperative sore throat and cough–A prospective randomized placebo-controlled study | |
| CN118593593A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating bronchitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |